Published in Cancer Immunol Immunother on December 24, 2014
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers (Basel) (2015) 0.90
Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85
Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79
Targeted Therapy in Oropharyngeal Squamous Cell Carcinoma: The Implications of HPV for Therapy. Rare Cancers Ther (2015) 0.75
Contrary melanoma-associated antigen-A expression at the tumor front and center: A comparative analysis of stage I and IV head and neck squamous cell carcinoma. Oncol Lett (2016) 0.75
Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res (2016) 0.75
Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. Cancers (Basel) (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res (2007) 2.57
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol (2005) 2.18
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol (2012) 2.01
Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol (2010) 1.96
Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol (2013) 1.91
Therapeutic cancer vaccines: are we there yet? Immunol Rev (2011) 1.86
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res (2008) 1.66
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer (2005) 1.55
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res (2012) 1.48
Antigen presentation by MHC class I and its regulation by interferon gamma. Curr Opin Immunol (1999) 1.41
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 1.33
Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol (2007) 1.32
Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res (2002) 1.30
Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer (2001) 1.25
Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck (2006) 1.23
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer (2003) 1.21
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma. Head Neck Pathol (2012) 1.05
Improving vaccine delivery using novel adjuvant systems. Hum Vaccin (2008) 1.05
Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer (2010) 1.01
HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells. Virology (2010) 0.96
TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol (2001) 0.96
Therapy with cultured T cells: principles revisited. Immunol Rev (1997) 0.93
Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. Int J Mol Med (2010) 0.93
Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res (2001) 0.92
The clinical implications of antitumor immunity in head and neck cancer. Laryngoscope (2012) 0.89
Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck (2012) 0.88
Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome. Curr Mol Med (2009) 0.86
Therapeutic vaccination for HPV induced cervical cancers. Dis Markers (2007) 0.85
High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck (2010) 0.83
Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer (2010) 0.80
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol (2007) 0.79
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
A test of climate, sun, and culture relationships from an 1810-year Chinese cave record. Science (2008) 3.94
Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J Virol (2005) 3.74
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med (2005) 3.65
Structural basis for the recognition of blood group trisaccharides by norovirus. J Virol (2007) 3.58
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21
MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem (2010) 2.85
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol (2012) 2.76
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol (2008) 2.64
Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res (2004) 2.28
Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.25
Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest (2002) 2.21
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol (2006) 2.09
Bevacizumab therapy for POEMS syndrome. Blood (2005) 2.03
What are the best management strategies for radiation-induced xerostomia? Laryngoscope (2013) 1.97
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol (2002) 1.97
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest (2003) 1.87
Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys (2007) 1.86
Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol (2003) 1.82
Role of glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem (2002) 1.82
HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene (2004) 1.82
Structural basis for the receptor binding specificity of Norwalk virus. J Virol (2008) 1.82
Effect of combined laser acupuncture on knee osteoarthritis: a pilot study. Lasers Med Sci (2008) 1.77
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol (2013) 1.75
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol (2009) 1.75
BK virus-associated urinary bladder carcinoma in transplant recipients: report of 2 cases, review of the literature, and proposed pathogenetic model. Hum Pathol (2013) 1.67
Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer (2007) 1.66
Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant (2004) 1.64
Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg (2008) 1.63
Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther (2004) 1.63
Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res (2006) 1.58
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res (2003) 1.57
Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation (2007) 1.56
Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest (2005) 1.55
TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. J Biol Chem (2008) 1.55
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J Immunol (2013) 1.53
Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol (2002) 1.51
Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer (2010) 1.50
Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol (2010) 1.46
Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys (2008) 1.46
The role of human papillomavirus in nongenital cancers. CA Cancer J Clin (2012) 1.46
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.46
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl (2002) 1.43
CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther (2009) 1.43
Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother (2004) 1.41
Interacinar c4d staining in pancreas allografts. Transplantation (2009) 1.41
Polysialylated neuropilin-2 is expressed on the surface of human dendritic cells and modulates dendritic cell-T lymphocyte interactions. J Biol Chem (2007) 1.39
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res (2009) 1.39
Stopping treatment can reverse acquired resistance to letrozole. Cancer Res (2008) 1.39
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. Clin Cancer Res (2009) 1.38
Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. J Virol (2012) 1.38
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood (2010) 1.38
Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res (2011) 1.35
B7-H4 expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma. Cancer Immunol Immunother (2011) 1.34
Prediction of antimicrobial peptides based on sequence alignment and feature selection methods. PLoS One (2011) 1.34
FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother (2008) 1.34
Functional analysis of the heat shock regulator HrcA of Chlamydia trachomatis. J Bacteriol (2002) 1.33
CPAF: a Chlamydial protease in search of an authentic substrate. PLoS Pathog (2012) 1.33
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.33
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol (2007) 1.32
Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32
Crystallography of a Lewis-binding norovirus, elucidation of strain-specificity to the polymorphic human histo-blood group antigens. PLoS Pathog (2011) 1.31
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer (2004) 1.31
Sigma28 RNA polymerase regulates hctB, a late developmental gene in Chlamydia. Mol Microbiol (2003) 1.29
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer (2004) 1.29
BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. Am J Transplant (2003) 1.28
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol (2004) 1.26
Oral inflammatory myofibroblastic tumor: case report and review of literature. Open Dent J (2011) 1.26
Primary histiocytic sarcoma arising in the head and neck with predominant spindle cell component. Diagn Pathol (2007) 1.26
Cryo-EM structure of a novel calicivirus, Tulane virus. PLoS One (2013) 1.26
Zinc and prostate cancer: a critical scientific, medical, and public interest issue (United States). Cancer Causes Control (2005) 1.25
Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol (2006) 1.25
Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant (2005) 1.24
Mutational analysis of the Chlamydia trachomatis dnaK promoter defines the optimal -35 promoter element. Nucleic Acids Res (2003) 1.24
Glucose oxidation modulates anoikis and tumor metastasis. Mol Cell Biol (2012) 1.23
Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer (2009) 1.22
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand. Drug Saf (2012) 1.21